MINJUVI

This brand name is authorized in Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Ireland, Israel, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug MINJUVI contains one active pharmaceutical ingredient (API):

1	Tafasitamab UNII QQA9MLH692 - TAFASITAMAB
	Tafasitamab is an Fc-enhanced monoclonal antibody that targets the CD19 antigen expressed on the surface of pre-B and mature B lymphocytes. Upon binding to CD19, tafasitamab mediates B-cell lysis. The Fc modification results in enhanced antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
	Read more about Tafasitamab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MINJUVI Powder for concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX12	Tafasitamab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02518627
EE	Ravimiamet	1861185
ES	Centro de información online de medicamentos de la AEMPS	1211570001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	121344
FR	Base de données publique des médicaments	65488266
IL	מִשְׂרַד הַבְּרִיאוּת	9021
IT	Agenzia del Farmaco	049606015
LT	Valstybinė vaistų kontrolės tarnyba	1093289
PL	Rejestru Produktów Leczniczych	100457769